基金业绩半年榜：汇添富旗下基金领跑，前海开源人工智能垫底

Core Insights - The A-share market concluded the first half of 2025 with a structural market trend, showing significant performance divergence among public funds, with an average return of 4.13% and over 87% of funds achieving positive returns [2][3] - The top-performing funds were primarily focused on the pharmaceutical and biotechnology sectors, while some funds heavily invested in new energy and artificial intelligence themes faced performance challenges [2][3] Fund Performance Overview - The top fund, Huatai Hong Kong Advantage Selection A, achieved a remarkable return of 86.48%, while the bottom fund, Qianhai Kaiyuan Artificial Intelligence A, recorded a loss of -20.57%, resulting in a performance gap of 107 percentage points [2][3][5] - The top 30 funds exhibited three notable characteristics: a strong rise of North Exchange theme funds, widespread success of pharmaceutical theme funds, and robust performance of Hong Kong Stock Connect innovative drug ETFs [3][5] Top 30 Funds Summary - The top three funds were: 1. Huatai Hong Kong Advantage Selection A (86.48%) 2. CITIC Construction Investment North Exchange Selection Two-Year Open A (82.45%) 3. Great Wall Pharmaceutical Industry Selection A (75.18%) [4][5] - The North Exchange 50 Index rose approximately 39.45% in the first half of the year, with related theme funds dominating the top ten performance rankings [3][5] Bottom 30 Funds Summary - The bottom fund, Qianhai Kaiyuan Artificial Intelligence A, had a return of -20.57%, with most underperforming funds being mixed and stock funds, showing losses between -12.43% and -20.57% [6][7] - The underperforming funds were heavily concentrated in technology and AI sectors, which faced significant downturns, contrasting with the strong performance of healthcare and innovative drug sectors in top-performing funds [8][9] Market Outlook - The A-share market is expected to present a "volatile upward" trend in the second half of 2025, supported by a series of domestic growth policies and monetary easing [11][12] - Investment strategies should balance high-growth sectors with stable dividend assets, focusing on innovative drugs and technology while considering potential external uncertainties [12]